4 Drug, Biotech Stocks Rising More Than 50% in 2025 With Room to Grow [Yahoo! Finance]
Mineralys Therapeutics, Inc. (MLYS)
Company Research
Source: Yahoo! Finance
This can be attributed to improved policies following several large drugmakers' drug pricing agreements with the Trump administration. Also, strong merger and acquisition (M&A) activity across the industry helped revive gains. The biotech sector has rallied 26% in the past six months, outperforming the S&P 500 index, as seen in the chart below. Image Source: Zacks Investment Research Innovation is likely to drive growth in the industry, with key areas like obesity, gene therapy, inflammation and neuroscience drawing investor attention. Regulatory activity remained healthy, with the FDA approving 44 novel therapies as of Dec. 22, 2025. M&A activity should remain strong in 2026. In this article, we discuss four drug/biotech stocks that have returned 50% or more in the year so far and have room for more growth in 2026 on the back of a solid portfolio and a promising pipeline. These are Mineralys Therapeutics MLYS, Lyell Immunopharma LYEL, Insmed INSM and Nektar Therapeutics NKTR. T
Show less
Read more
Impact Snapshot
Event Time:
MLYS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MLYS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MLYS alerts
High impacting Mineralys Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
MLYS
News
- Fund Discloses Increased Mineralys Bet Amid 200% Stock Run as New Drug Application Nears [Yahoo! Finance]Yahoo! Finance
- Mineralys Therapeutics (NASDAQ:MLYS) was given a new $52.00 price target on by analysts at Stifel Nicolaus. They now have a "buy" rating on the stock.MarketBeat
- Mineralys Therapeutics’ Phase 3 Launch-HTN Trial of Lorundrostat Recognized in Inaugural Journal of the American Medical Association (JAMA) “Research of the Year” RoundupGlobeNewswire
- A Look at Mineralys Therapeutics (MLYS) Valuation After Findell Capital's Major New Investment [Yahoo! Finance]Yahoo! Finance
- Mineralys Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]Yahoo! Finance
MLYS
Earnings
- 11/10/25 - Beat
MLYS
Sec Filings
- 11/24/25 - Form 4
- 11/21/25 - Form 4
- 11/20/25 - Form 144
- MLYS's page on the SEC website